Collaborative Healthcare Professionals Approach in Monitoring of Patient Centered Outcomes Through Pathways (CHAMP-Path)
The aim of this study is to determine if by providing a collaborative, integrated pathway-based healthcare compared to the usual healthcare, whether or not this would be superior in reducing the length of hospital stay across five high frequency /high risk medical diagnoses: Acute Venous Thromboembolism, Acute Kidney Injury, Community Acquired Pneumonia, Adult Left Ventricular Heart Failure, and Asthma.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Health Services Research
|Official Title:||A Pragmatic Randomized Controlled Trial of Patient-Centered Integrated Clinical Pathways Based Versus Usual Care in an Academic Center: National Guard Health Affairs Western Region Experience|
- Decrease in length of hospital stay by two days [ Time Frame: During hospitalization period of 7 to 10 days ] [ Designated as safety issue: No ]
- 30-Day Rehospitalization [ Time Frame: After discharge up to 30 days ] [ Designated as safety issue: No ]To determine the effect of the pathway-based care versus usual care on 30-day rehospitalization rates for the same diagnosis
- Determinants of the Length of Stay [ Time Frame: Upon admission until discharge ] [ Designated as safety issue: No ]
- Pathway Care Specific Clinical Outcomes [ Time Frame: Upon admission until discharge ] [ Designated as safety issue: No ]For pathway care, there are specific targeted outcomes that ought to be met.
|Study Start Date:||March 2012|
|Estimated Study Completion Date:||October 2016|
|Estimated Primary Completion Date:||October 2016 (Final data collection date for primary outcome measure)|
|Active Comparator: Patients on Pathway Care||
Other: Pathway-Based Care
Patients who are randomly allocated to Pathway Care will be treated by the Pathway Clinical Teaching Unit as well as other collaborative healthcare professionals (pharmacists, nurses, health educators, nutritionists, and social workers). The Pathway Care physicians will have access to the Clinical Care Plan on the QuadraMed, which is a detailed, organized, day-to-day treatment plan that includes pre-set orders and medications. Physicians for the patients on Usual Care will not have access to this information, and the collaborative healthcare will only be provided upon consultation.
|No Intervention: Patients on Usual Care|
This study is a pragmatic randomized controlled trial. To date, there is a scarcity of randomized controlled trials looking at pathway-based, patient-centered healthcare versus usual care in several high-risk or high volume diagnoses that account for the vast majority of hospitalizations in medical settings.
In this study, the pathway care intervention is a collaborative effort that involves healthcare professionals from multiple departments, including pharmacists, health educators, nurses, social workers, nutritionists, and quality management.
For patients allocated to the usual care, these healthcare professionals will deliver standardized care when consulted. For pathway care patients, this collaborative healthcare will be default.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01561885
|Contact: Saliman Karsou, MD||+966122266666 ext 22170||KarsouSA@ngha.med.sa|
|Contact: Mujtaba Quadri, MD||+966122266666 ext 22170||QuadriMU@ngha.med.sa|
|King Khalid National Guard Hospital||Recruiting|
|Jeddah, Makkah, Saudi Arabia, 21423|
|Contact: Saliman Karsou, MD +966122266666 ext 22170 KarsouSA@ngha.med.sa|
|Principal Investigator: Saliman Karsou, MD|
|Principal Investigator:||Mujtaba Quadri, MD||National Guard Health Affairs|
|Principal Investigator:||Sherine Esmail, PharmD||National Guard Health Affairs|
|Principal Investigator:||Saliman Karsou, MD||National Guard Health Affairs|
|Principal Investigator:||Abdulhameed Gasim, MD||National Guard Health Affairs|
|Principal Investigator:||Zeyad Zahrani, MD||National Guard Health Affairs|
|Principal Investigator:||Majed Al Jeraisy, PharmD||King Abdullah International Medical Research Center|